Comprehensive hereditary cancer panel - 54 genes

What is the Comprehensive Cancer Predisposition Genetic Panel?

This is an innovative genetic test to determine the risk of cancer, especially in people with a family history of cancer. It includes 54 genes associated with more than 30 types of cancer.

Who is the panel designed for?

The cancer predisposition test can be performed by any adult who wants to gain knowledge on the subject and consciously take care of their health.

Performing the test should consider especially:

• people who have family members who were diagnosed with malignant neoplasm at a young age (before the age of 50);
• persons with a clear family burden of malignant neoplasms (malignant neoplasm diagnosed in 3 or more close relatives);
• people with diagnosed malignant neoplasm - in order to determine the basis of the disease and precise choice of therapy.

What does the test consist of?

The test is performed from a blood sample, using the Next Generation Sequencing (NGS) method. This technology allows you to check very precisely all the sites within the mentioned 54 genes in your DNA that may contain a pathogenic variant (mutation), which can cause the development of hereditary cancer in the future. You can find a detailed description of the technology further on.

What is the scope of the panel?

The panel evaluates the risk of developing cancers of 10 organs and organ systems, as well as non-specific cancer syndromes.

Some of the diseases covered by the panel are:

• cancer of the breast gland;
• cancer of the large intestine;
• cancer of the stomach;
• medullary thyroid cancer;
• melanoma;
• ovarian cancer;
• cancer of the pancreas;
• parathyroid cancer;
• pheochromocytoma;
• renal cell carcinoma;
• and others.

Genes to be analyzed:

APC, ATM, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDC73, CDH1, CDK4, CDKN1B, CDKN2A, CHEK2, DICER1, EPCAM, FH, FLCN, GREM1, MAX, MEN1, MET, MITF, MLH1, MLH3, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NTHL1, PALB2, PMS2, POLD1, POLE, POT1, PTCH1, PTEN, RAD51C, RAD51D, RET, RNF43, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, STK11, SUFU, TMEM127, TP53, VHL.

Testing technology - details:

The genetic panels we offer are performed using the Next Generation Sequencing (NGS) method, which provides very high sensitivity and specificity of the test.

This technology makes it possible, first of all, to analyze the entire coding sequence and those fragments of the non-coding sequence of individual genes that may contain pathogenic changes (variants) that can lead to the development of cancer.

Other genetic tests offered on the market (e.g. PCR tests) focus exclusively on the analysis of one or a few selected sites (or positions) in the gene, where pathogenic variants (commonly referred to as mutations) most often appear. In this type of genetic testing, rarer variants are ignored, making it impossible to reliably estimate cancer risk.

The sensitivity of detection of single nucleotides in the case of NGS sequencing used by us is 99.93%, thanks to which the genetic panels offered by us rank among the top competitive tests available on the Polish market.

The result of the test allows you to estimate your risk of developing cancer from genetic causes. With this knowledge, you can consciously take care of your health and take relevant measures, such as making lifestyle changes and, together with your doctor, adjusting the type and frequency of check-ups. What's more, if you do get sick, knowledge of your genetic status can help you choose the best method and start treatment quickly.

Worth knowing:

• Cancer is one of the leading causes of death worldwide.
• About 10% of cancers are hereditary. The risk of passing on and inheriting a harmful genetic variant is as high as 50%.
• Up to 40% of cancer-related deaths can be avoided with lifestyle changes.

• After purchasing the test panel, you will be contacted within 2 business days by our medical staff member for a medical interview and order form.
• The test is intended for adults. No referral is required.
• In the case of minors, a referral from a Damian Medical Center clinical geneticist is required, and the purchase can be made only by an adult who is the parent or legal guardian of the minor.
• The test involves taking a blood sample and requires no special preparation. You do not need to be fasting.
• The waiting time for the result is a maximum of 30 working days. The result is sent to the e-mail address provided during the medical interview.
• A positive or inconclusive test result allows you to purchase consultations with a geneticist and a psychologist at a cost of PLN 1 for each of these services (to be used within 3 months of receiving the result). The purchase is possible only in the facilities of the Damian Medical Center.